Known as donanemab, the medication clears amyloid plaque from the brain. In a late trial, the drug slowed memory and thinking declines in...
But there were some risks noted in the results. The Lilly trial involved 1,700 patients, three of whom died during the study. Two of those deaths were attributed to brain swelling or microbleeds called amyloid-related imaging abnormalities .
"We are encouraged by the potential clinical benefits that donanemab may provide, although like many effective treatments for debilitating and fatal diseases, there are associated risks that may be serious and life-threatening," said Dr. Mark Mintun, group vice president Neuroscience Research & Development at Lilly. "We note that these results suggest that people in the early pathological stage of disease could be the most responsive to therapeutics targeting amyloid.
About 52% of the patients in the trial were able to stop taking the medication by one year because of its effectiveness. About 72% could do so by a year and a half, the company said. In the trial, a group with intermediate levels of a brain protein known as tau had a 35% slowing in cognitive and functional decline. In the intermediate group combined with a group with higher tau levels, slowing in decline was 22%.
This new class of medicines is different because of “the amount of amyloid they can clear and how quickly they can clear it,” Skovronsky toldAnother new drug, Eisai and Biogen's Leqembi, was approved in January under an accelerated approval process. It may receive full approval by July,Lilly has also sought accelerated approval, but the FDA rejected the application in January because it wanted more data, according toDonanemab is given by infusion once monthly.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Experimental Drug Slows Alzheimer’s in Large Study, Eli Lilly SaysAn experimental Eli Lilly drug slowed cognitive and functional decline for people with early-stage Alzheimer’s disease in a new study that could support regulatory approval and commercial sale
Read more »
Study: Experimental Alzheimer’s drug slows declineStudy: Experimental Alzheimer’s drug slows decline.
Read more »
Eli Lilly says experimental drug slows Alzheimer's worseningEli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease
Read more »
Experimental Alzheimer's drug slows cognitive declines in large trial, drugmaker Eli Lilly says | CNNAn experimental Alzheimer's medication slowed declines in patients' ability to think clearly and perform daily tasks by more than a third in a large clinical trial, drugmaker Eli Lilly said Wednesday.
Read more »
Eli Lilly says experimental drug slows Alzheimer's worseningEli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease.
Read more »
Eli Lilly says experimental drug slows Alzheimer’s worseningEli Lilly and Co. said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study.
Read more »